Status: Recruiting
Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade
This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.
Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: EuroCityClinic LLCUpdated: Aug 19, 2025Locations: 1
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 [+8]
Presence of clinically significant cardiovascular disease: severe or unstable is... [+15]